| Identification | Back Directory | [Name]
QL-X-138 | [CAS]
1469988-63-3 | [Synonyms]
QL-X-138
2-Propenamide, N-[2-methyl-5-[2-oxo-9-(1H-pyrazol-4-yl)benzo[h]-1,6-naphthyridin-1(2H)-yl]phenyl]- | [Molecular Formula]
C25H19N5O2 | [MDL Number]
MFCD34567267 | [MOL File]
1469988-63-3.mol | [Molecular Weight]
421.45 |
| Hazard Information | Back Directory | [Uses]
QL-X-138 is a potent and selective BTK/MNK dual kinase inhibitor, exhibits covalent binding to BTK and non-covalent binding to MNK. QL-X-138 shows IC50s of 9.4 nM, 107.4 nM and 26 nM for BTK, MNK1 and MNK2 kinases respectively. QL-X-138 also shows anti-dengue virus 2 activity, with an IC50 of 3.5 μM. QL-X-138 can be used for the research of B-cell malignancies[1][2]. | [Definition]
ChEBI: N-[2-methyl-5-[2-oxo-9-(1H-pyrazol-4-yl)-1-benzo[h][1,6]naphthyridinyl]phenyl]-2-propenamide is a naphthyridine derivative. | [References]
[1] Wu H, et, al. Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan;30(1):173-81. DOI:10.1038/leu.2015.180
[2] Wispelaere M, et, al. Discovery of host-targeted covalent inhibitors of dengue virus. Antiviral Res. 2017 Mar;139:171-179. DOI:10.1016/j.antiviral.2016.12.017 |
|
|